C4 Therapeutics (CCCC) Shares Outstanding (Weighted Average) (2019 - 2026)

C4 Therapeutics' Shares Outstanding (Weighted Average) history runs 8 years deep, the most recent figure standing at $126.1 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 77.99% year-over-year to $126.1 million; the TTM figure through Mar 2026 stood at $126.1 million (up 77.99% YoY), while the FY2025 annual figure was $82.9 million, up 19.49% from the prior year.
• Shares Outstanding (Weighted Average) was $126.1 million for Q1 2026 at C4 Therapeutics, up from $28.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $126.1 million in Q1 2026 to a low of $28.7 million in Q4 2025.
• Historically, Shares Outstanding (Weighted Average) has averaged $61.0 million across 5 years, with a median of $49.6 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Weighted Average) sank 58.61% in 2025, then jumped 77.99% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $48.9 million in 2022, then increased by 1.59% to $49.6 million in 2023, then surged by 39.75% to $69.4 million in 2024, then tumbled by 58.61% to $28.7 million in 2025, then surged by 339.08% to $126.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $126.1 million (Q1 2026), $28.7 million (Q4 2025), and $72.6 million (Q3 2025), per Business Quant data.